Faron Pharmaceuticals

0.45 EUR

+0.67 %

5,703 following
Corporate customer

FARON

First North Finland

Biotechnology & Pharmaceuticals

Health Care

+0.67 %
-10.28 %
-76.15 %
-77.48 %
-78.31 %
-80.27 %
-86.84 %
-88.17 %
-86.54 %

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

Read more
Market cap
91.27M EUR
Turnover
352.23K EUR
P/E (adj.) (26e)
-4.35
EV/EBIT (adj.) (26e)
-5
P/B (26e)
78
EV/S (26e)
23,729.9
Dividend yield-% (26e)
-
Coverage
Recommendation
Buy
Target price
0.75 EUR
Updated
2026-03-11
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 2026-03-12

Latest extensive report

Released: 2022-08-23

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
4/5
2026

General meeting '26

26/8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
H.C. Wainwright At-Home Fireside Chat series: Faron Pharmaceuticals Transcript Part 2: Summary Luis Santos: Have you provided guidance on the current cash runway and funding plans to continue operations? Juho Jalkanen: Currently, we are funded until the end of 2027. So, we are funded...
yesterday
by Vino Pino
44
Some highlights from the discussion: The upcoming BEXERA study was detailed more closely during the discussion: It is a randomized study where bexmarilimab is tested in combination with standard of care (azacitidine) against a control group. Jalkanen confirmed that the study is designed...
4/27/2026, 6:05 PM
by Kulkuri
41
H.C. WainwrightIn haastattelussa siis Juho. Haastattelija on Ph.D. ja ihan tuntuu olevan kärryillä ja tekevän hyviä kysymyksiä. Etukäteen tuskin on kaikkea kirjoitettu, koska kysyy detaljeja, johon Juho ei tiedä vastausta ulkomuistista. H.C. on se analyysitalo, jolla on poikkeava...
yesterday
by Vino Pino
37
These have likely been done using Clever-1 immunostaining from tissue samples. Faron has developed its own model for this using Aiforia’s Create tool. A short description of Faron’s use case can be found on Aiforia’s website: Faron Pharmaceuticals case study: using AI to perform ...
4/27/2026, 8:59 PM
by jerej
26
PubMed Central (PMC) The Conflicting Role of Myeloid Cells in CAR-T Cell Therapy Chimeric antigen receptor T (CAR-T) cell therapy is revolutionizing cancer treatment in hematological malignancies, but challenges related to the tumor microenvironment have hindered CAR-T success, especially...
yesterday
by poiju
19
News buzz about the CoH trial: Aren’t they also heavily involved in CAR-T therapies over there? Faron and City of Hope to develop phase II trial of bexmarilimab for r/r MDS Key takeaways: Targeted Therapy: Bexmarilimab, a macrophage-targeting anti–Clever-1 antibody, will be tested...
yesterday
by Kulkuri
13
However, in this Kelonia deal, it is worth noting that this is part of a larger trend where in vivo CAR-T cell therapies are believed to replace previous in vitro CAR-T therapies. Current in vitro CAR-T therapies have proven commercially unsatisfactory, and the development costs ...
yesterday
by jerej
13
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.